肝硬化患者的肝静脉压力梯度变化可靠吗？ - Suppr

Suppr

超能文献

Can We Rely on Changes in HVPG in Patients with Cirrhosis?

作者信息

Garcia-Tsao Guadalupe

机构信息

Digestive Diseases Section, Yale University School of Medicine, New Haven, CT.

Digestive Diseases Section, VA-Connecticut Healthcare System, West Haven, CT.

出版信息

Hepatology. 2021 Dec;74(6):2945-2947. doi: 10.1002/hep.32159. Epub 2021 Oct 28.

DOI:10.1002/hep.32159

PMID:34569630

Abstract

摘要

相似文献

Can We Rely on Changes in HVPG in Patients with Cirrhosis?肝硬化患者的肝静脉压力梯度变化可靠吗？

Hepatology. 2021 Dec;74(6):2945-2947. doi: 10.1002/hep.32159. Epub 2021 Oct 28.

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.恩卡司他用于治疗非酒精性脂肪性肝炎相关肝硬化伴严重门静脉高压的随机安慰剂对照试验。

J Hepatol. 2020 May;72(5):885-895. doi: 10.1016/j.jhep.2019.12.010. Epub 2019 Dec 21.

Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.病毒抑制对丙型肝炎肝硬化伴门静脉高压患者肝静脉压力梯度的影响。

J Viral Hepat. 2017 Oct;24(10):823-831. doi: 10.1111/jvh.12706. Epub 2017 Apr 10.

Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.无创性天冬氨酸转氨酶与血小板比值指数与肝硬化患者有创性肝静脉压力梯度密切相关。

Indian J Gastroenterol. 2018 Jul;37(4):335-341. doi: 10.1007/s12664-018-0879-0. Epub 2018 Sep 3.

A computational model of the hepatic circulation applied to analyze the sensitivity of hepatic venous pressure gradient (HVPG) in liver cirrhosis.一种用于分析肝硬化患者肝静脉压力梯度（HVPG）敏感性的肝循环计算模型。

J Biomech. 2017 Dec 8;65:23-31. doi: 10.1016/j.jbiomech.2017.09.023. Epub 2017 Oct 6.

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.口服抗病毒治疗对丙型肝炎病毒相关性肝硬化患者肝静脉压力梯度和全身血液动力学的影响。

Gastroenterology. 2017 Nov;153(5):1273-1283.e1. doi: 10.1053/j.gastro.2017.07.016. Epub 2017 Jul 20.

Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.抗病毒治疗可降低 HBeAg 阴性慢性乙型肝炎和显著门静脉高压所致肝硬化患者的门静脉压力。

J Hepatol. 2009 Sep;51(3):468-74. doi: 10.1016/j.jhep.2009.05.031. Epub 2009 Jul 3.

Novel imaging-based approaches for predicting the hepatic venous pressure gradient in a porcine model of liver cirrhosis and portal hypertension.基于新型影像学方法预测肝硬化和门静脉高压症猪模型的肝静脉压力梯度。

Life Sci. 2021 Jan 1;264:118710. doi: 10.1016/j.lfs.2020.118710. Epub 2020 Nov 2.

CT perfusion imaging of the liver and the spleen in patients with cirrhosis: Is there a correlation between perfusion and portal venous hypertension?肝硬化患者肝脏和脾脏的 CT 灌注成像：灌注与门静脉高压之间是否存在相关性？

Eur Radiol. 2017 Oct;27(10):4173-4180. doi: 10.1007/s00330-017-4788-x. Epub 2017 Mar 20.

Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.辛伐他汀降低肝硬化和门静脉高压患者的门静脉压力：一项随机对照试验。

Gastroenterology. 2009 May;136(5):1651-8. doi: 10.1053/j.gastro.2009.01.043. Epub 2009 Jan 24.

引用本文的文献

Akkermansia muciniphila improve cognitive dysfunction by regulating BDNF and serotonin pathway in gut-liver-brain axis.阿克曼氏菌（Akkermansia muciniphila）通过调节肠-肝-脑轴中的 BDNF 和血清素途径改善认知功能障碍。

Microbiome. 2024 Sep 28;12(1):181. doi: 10.1186/s40168-024-01924-8.

Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review.β受体阻滞剂治疗门静脉高压症的疗效异质性：系统评价。

Hepatol Commun. 2024 Jan 29;8(2). doi: 10.1097/HC9.0000000000000321. eCollection 2024 Feb 1.

Pharmacotherapies for Portal Hypertension: Current Status and Expanding Indications.门静脉高压的药物治疗：现状与适应证拓展

Curr Hepatol Rep. 2023 Mar;22(1):44-50. doi: 10.1007/s11901-023-00600-z. Epub 2023 Feb 20.

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.机器学习肝组织学评分与非酒精性脂肪性肝炎肝硬化门静脉高压评估相关。

Aliment Pharmacol Ther. 2023 Feb;57(4):409-417. doi: 10.1111/apt.17363. Epub 2023 Jan 17.

Portal pressure reductions induced by nonselective beta-blockers improve outcomes and decrease mortality in patients with cirrhosis with and without ascites.非选择性β受体阻滞剂引起的门静脉压力降低可改善肝硬化伴或不伴腹水患者的预后并降低死亡率。

Clin Liver Dis (Hoboken). 2022 Jun 3;20(1):1-4. doi: 10.1002/cld.1210. eCollection 2022 Jul.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验